共 162 条
[1]
Forner A(2018)Hepatocellular carcinoma Lancet 391 1301-1314
[2]
Reig M(2010)Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study Cardiovasc Intervent Radiol 33 41-52
[3]
Bruix J(2016)Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: a meta-analysis Dig Liver Dis. 48 571-577
[4]
Lammer J(2016)Unresectable hepatocellular carcinoma: radioembolization versus chemoembolization: a systematic review and meta-analysis Cardiovasc Interv Radiol 39 1580-1588
[5]
Malagari K(2013)Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study Hepatology 57 1826-1837
[6]
Vogl T(2016)Yttrium-90 radioembolization as a salvage treatment following chemoembolization for hepatocellular carcinoma J Vasc Interv Radiol 27 1123-1129
[7]
Pilleul F(2011)EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization J Hepatol 55 1309-1316
[8]
Denys A(2013)mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE) Ann Oncol 24 965-973
[9]
Watkinson A(2012)Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models Radiology 262 708-718
[10]
Facciorusso A(2011)Principles and applications of diffusion-weighted imaging in cancer detection, staging, and treatment follow-up Radiographics. 31 1773-1791